← ANALYST RATINGS · TIPRANKS
Edgewise Therapeutics (EWTX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $52.33, the highest $60.00, the lowest $36.00. The average is +40.7% from the last price of $37.19.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $53.00 | Buy | +42.5% | Initiated | 15.10.26on TipRanks Oct 16 08:15 | +2.9%next day −1.5% | ↗ |
| Lander Egana Gorrono★★★★★★★★★★#9556 · hits 0% · avg −7.2% | H.C. Wainwright | $57.00 | Buy | +53.3% | Reiterated | 14.10.26on TipRanks 07:08 | +3.1%next day +2.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $43.00 → $38.00−11.6% | Hold | +2.2% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $42.00 → $37.00−11.9% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $42.00 → $37.00−11.9% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $42.00 → $37.00−11.9% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $44.00 → $39.00−11.4% | Hold | +4.9% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $41.00 → $37.00−9.8% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $51.00 | Buy | +37.1% | Reiterated | 13.10.26on TipRanks 07:09 | −5.6%next day +3.1% | ↗ |
| Lander Egana Gorrono★★★★★★★★★★#9556 · hits 0% · avg −7.2% | H.C. Wainwright | $57.00 | Buy | +53.3% | Reiterated | 08.10.26on TipRanks 11:15 | −0.4%next day −1.0% · 5 days −2.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $47.00 → $43.00−8.5% | Hold | +15.6% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $47.00 → $42.00−10.6% | Hold | +12.9% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $48.00 → $42.00−12.5% | Hold | +12.9% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $47.00 → $42.00−10.6% | Hold | +12.9% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $47.00 → $44.00−6.4% | Hold | +18.3% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $47.00 → $41.00−12.8% | Hold | +10.2% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | — | Buy | — | Reiterated | 23.09.26on TipRanks Sep 25 04:35 | −7.1%next day +0.4% · 5 days −0.4% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $53.00 | Buy | +42.5% | Reiterated | 23.09.26on TipRanks 09:08 | −7.1%next day +0.4% · 5 days −0.4% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 23.09.26on TipRanks 07:55 | −7.1%next day +0.4% · 5 days −0.4% | ↗ |
| Lander Egana Gorrono★★★★★★★★★★#9556 · hits 0% · avg −7.2% | H.C. Wainwright | $57.00 | Buy | +53.3% | Reiterated | 23.09.26on TipRanks Sep 21 06:25 | −3.1%next day −0.3% · 5 days −9.8% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $36.00 | Hold | −3.2% | Reiterated | 22.09.26on TipRanks Sep 23 07:50 | −0.3%next day −7.1% · 5 days −10.8% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $59.00 | Buy | +58.6% | Reiterated | 22.09.26on TipRanks Sep 23 07:35 | −0.3%next day −7.1% · 5 days −10.8% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $53.00 → $60.00+13.2% | Buy | +61.3% | Assigned | 20.08.26on TipRanks 07:25 | −5.9%next day +1.6% · 5 days +1.0% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $36.00 | Hold | −3.2% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | −0.3%next day −1.9% · 5 days 0.0% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $55.00 | Buy | +47.9% | Reiterated | 07.08.26on TipRanks 08:45 | −2.6%next day +2.5% · 5 days +1.1% | ↗ |
| Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% | Oppenheimer | $51.00 | Buy | +37.1% | Initiated | 09.07.26on TipRanks 07:25 | +3.6%next day −6.5% · 5 days −20.9% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $41.00 → $51.00+24.4% | Buy | +37.1% | Reiterated | 06.07.26on TipRanks 08:25 | +0.5%next day +8.0% · 5 days +3.2% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $52.00 → $66.00+26.9% | Buy | +77.5% | Reiterated | 01.06.26on TipRanks 14:25 | +17.6%next day −7.6% · 5 days −10.9% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $51.00 | Buy | +37.1% | Reiterated | 09.02.26on TipRanks 07:26 | +3.5%next day +2.7% · 5 days +1.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Edgewise Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $50.89 at a price of $40.60 (+25.3%); now: $51.11 at $37.19 (+37.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 5 | 4 | 3 | 0 | 0 |
| Buy | 14 | 20 | 23 | 18 | 12 | 10 |
| Hold | 1 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.53 (from $-0.64 to $-0.37). Last quarter: $-0.53.
Best top-analyst consensus in the sector · Healthcare
About Edgewise Therapeutics
- CEO: Kevin Koch
- Employees: 127
- 1715 38th Street, Boulder, CO, 80301, US
- www.edgewisetx.com
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗